Vijay Pande, a general partner at Andreessen Horowitz who founded the firm’s a16z Bio + Health strategy, announced that he is stepping down from his role.

Since its founding in 2014, a16z Bio + Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund that closed in 2022. However, it’s now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio + Health announced that it will manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly.

a16z Bio + Health backs digital health startups and companies at the intersection of AI, computation, and biology.

Pande’s investments include Devoted Health, an individualized medical plan provider; Function Health, a personalized lab testing startup; and Freenome, a company aiming to detect cancer through blood draws. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University.

The remaining partners on the a16z Bio + Health team are Jorge Conde, Julie Yoo, and Vineeta Agarwala.